10 recruiting, 8 completed, 3 active not recruiting, 3 terminated. 16 Phase 2, 14 Phase 3, 10 Phase 1.
Follow this drug Literature Review of Levoleucovorin trials Research Report on Levoleucovorin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 600 | 2027-02-01 | 2026-09-14 |
| A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) MK-2010, Pembrolizumab, 5-Fluorouracil - Malignant Neoplam, Advanced Solid Tumors | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 480 | 2026-10-27 | 2026-10-08 |
| A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer SHR-A1811, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab - Advanced Colorectal Cancer | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 300 | 2026-08-28 | 2026-09-10 |
| Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) Pembrolizumab, I-DXd, Leucovorin - Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 298 | 2025-07-30 | 2026-10-16 |
| Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma Tislelizumab, Oxaliplatin injection, Levo-Leucovorin - Gastric Cancer | Phase 3 | Recruiting | Fujian Cancer Hospital | 269 | 2025-06-07 | 2025-07-20 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2025-06-05 | 2026-10-21 |
| A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy Amivantamab, Cetuximab, Bevacizumab - Colorectal Neoplasms | Phase 3 | Recruiting | Janssen Research & Development, LLC | 700 | 2024-12-12 | 2026-09-25 |
| A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer Amivantamab, Cetuximab, 5-fluorouracil - Colorectal Neoplasms | Phase 3 | Recruiting | Janssen Research & Development, LLC | 1000 | 2024-10-18 | 2026-09-25 |
| Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine - Gastroesophageal Junction, Gastroesophageal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 160 | 2024-09-20 | 2026-10-07 |
| A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin - Colorectal Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 220 | 2024-06-20 | 2026-10-20 |
| Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer Tislelizumab, Oxaliplatin, Levo-Leucovorin - Gastric Cancer | Phase 2 | Unknown | Fujian Cancer Hospital | 36 | 2024-01-01 | 2024-01-09 |
| Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer cadonilimab, irinotecan, Oxaliplatin - Colorectal Cancer | Phase 2 | Unknown | Fujian Cancer Hospital | 20 | 2023-11-19 | 2023-11-15 |
| Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors Futibatinib, Pembrolizumab, Cisplatin - Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma | Phase 2 | Active not recruiting | Taiho Oncology, Inc. | 53 | 2023-07-13 | 2026-09-01 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab Oxaliplatin, Levo-Leucovorin, 5-fluorouracil - Gastric Cancer Stage IV | Phase 1 / Phase 2 | Recruiting | Fujian Cancer Hospital | 51 | 2023-02-16 | 2025-02-27 |
| A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer tucatinib, trastuzumab, bevacizumab - Colorectal Neoplasms | Phase 3 | Recruiting | Seagen, a wholly owned subsidiary of Pfizer | 400 | 2022-10-24 | 2026-07-22 |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014). Pembrolizumab, Lenvatinib, Cisplatin - Metastatic Esophageal Squamous Cell Carcinoma | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 863 | 2021-07-28 | 2026-08-21 |
| Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) Pembrolizumab, Lenvatinib, Oxaliplatin - Advanced/Metastatic Gastroesophageal Adenocarcinoma | Phase 3 | Completed | Merck Sharp & Dohme LLC | 895 | 2020-12-30 | 2026-04-28 |
| A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer Encorafenib, Cetuximab, Oxaliplatin - Neoplasms | Phase 3 | Active not recruiting | Pfizer | 841 | 2020-12-21 | 2026-06-11 |
| Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) Olaparib, 5-FU, Bevacizumab - Metastatic Colorectal Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 335 | 2020-08-19 | 2024-10-29 |
Showing 20 of 32. Sign in to see all of them.
Colorectal Neoplasms (14) · Stomach Neoplasms (5) · Colonic Neoplasms (4) · Esophageal Squamous Cell Carcinoma (4) · Parkinson Disease 4, Autosomal Dominant Lewy Body (4) · Adenocarcinoma Of Esophagus (3) · Esophageal Neoplasms (3) · Neoplasm Metastasis (3) · Rectal Neoplasms (3) · Burkitt Lymphoma (2) · Carcinoma, Non-Small-Cell Lung (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Neoplasms (2)
Merck Sharp & Dohme LLC (8) · Fujian Cancer Hospital (5) · Acrotech Biopharma Inc. (2) · Janssen Research & Development, LLC (2) · NuCana plc (2) · Asan Medical Center (1) · Bayer (1) · Children's Oncology Group (1) · Isofol Medical AB (1) · National Cancer Institute (NCI) (1) · Ono Pharmaceutical Co., Ltd. (1) · Pfizer (1) · SCRI Development Innovations, LLC (1) · Seagen, a wholly owned subsidiary of Pfizer (1) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1)
United States (19) · China (15) · France (12) · Italy (12) · South Korea (12) · Germany (11) · United Kingdom (11) · Belgium (10) · Japan (10) · Spain (10) · Taiwan (10) · Canada (9) · Chile (9) · Turkey (Türkiye) (8) · Australia (7)
Afsaneh Barzi, MD (1) · Ahmed Sawas, MD (1) · Andrea Biondi (1) · Elisabeth Oelmann, MD PhD (1) · Erin H Breese (1) · Johanna C Bendell, M.D. (1) · Kristoffer Derwinger, MD PhD (1) · Lewis B Silverman (1) · Marc Peeters (1) · Marc Van den Eynde (1)
PMID 23532888, PMID 33533655, PMID 34779646, PMID 36763936, PMID 38695479, PMID 38749110, PMID 39723627, PMID 39863775, PMID 40444708, PMID 40448579, PMID 41230651, PMID 42218533
2023 (4), 2017 (2), 2019 (2), U10CA180886 (2), 2008 (1), 2025 (1), P30CA014089 (1)